UK’s NICE Recommends Against Lynparza Tablets on NHS for Advanced, Platinum-sensitive Ovarian Cancers

UK’s NICE Recommends Against Lynparza Tablets on NHS for Advanced, Platinum-sensitive Ovarian Cancers
The U.K.’s National Institute of Health and Care Excellence (NICE) has decided not to recommend Lynparza (olaparib) tablets as maintenance treatment for women with relapsed ovarian cancer who respond to platinum-based chemotherapy due to unsatisfactory cost-effectiveness. However, this is not the advisory committee's final guidance on the therapy, and its decision could be reversed following the ongoing consultation period. AstraZeneca and Merck (known as MSD outside the U.S. and Canada) were looking for NICE's recommendation for Lynparza use (two 150 mg tablets a day) on the U.K.'s National Health System (NHS) for women with high-grade epithelial ovarian, fallopian tube, or primary cancer of the peritoneum, regardless of BRCA mutations. Although clinical experts explained to the committee that Lynparza extends the time until cancer progression compared with routine surveillance and that the U.K. has worse survival rates and outcomes than other developed countries, NICE considered that “cost-effectiveness estimates are substantially above the range normally considered cost effective,” as written in its draft guidance. “Olaparib does not meet NICE’s end-of-life or Cancer Drugs Fund criteria. Therefore, it is not recom
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *